A high-throughput, human cell-based platform for screening peptide-guided ubiquibodies (uAbs), which connects generative peptide design to functional mammalian selection and establishes a scalable strategy for CRISPR-like proteome perturbation.
Abstract
Targeted protein degradation (TPD) offers a route to eliminate disease-driving proteins that remain inaccessible to conventional inhibitors. However, degrader discovery remains low-throughput, labor-intensive, and dependent on randomized libraries or non-human display systems, limiting functional selection in mammalian cells. Here, we present a high-throughput, human cell-based platform for screening peptide-guided ubiquibodies (uAbs). These genetically encodable, doxycycline-inducible degraders fuse peptide guides generated by protein language models to the CHIPΔTPR E3 ligase domain, creating a modular, CRISPR-like system for programmable TPD. For each target, we introduce a pooled uAb library into the corresponding fluorescent reporter cell line, isolate cells with reduced target abundance by FACS, and recover enriched peptide guides by sequencing. For β-catenin, enriched uAbs reduced endogenous β-catenin abundance and Wnt signaling in DLD1 cells. GFAP-directed uAbs reduced endogenous GFAP abundance and cell viability in U251 glioblastoma cells, while EWS::FLI1-directed uAbs reduced fusion oncoprotein abundance, suppressed EWSAT1 expression, and increased apoptosis in Ewing sarcoma models. Finally, a screen using endogenously tagged GATA2 further identified uAbs that reduced GATA2 under native genomic regulation. Overall, our platform connects generative peptide design to functional mammalian selection and establishes a scalable strategy for CRISPR-like proteome perturbation.
Abstract Targeted protein degradation has emerged as a powerful strategy for modulating intracellular proteins, particularly those lacking traditional small‐molecule binding pockets. While protein‐based degraders expand this approach to undruggable targets, they typically require intracellular expression in target cell...
Aniekan M. Okon, Keith M. Cheah, Oscar J. Molina et al.· Protein Science· 0 citations
Heterobifunctional compounds (HBCs) that facilitate target protein degradation (TPD) by recruiting an E3 ligase complex have emerged as therapeutic options for cancer. Current screening approaches often prioritize protein degradation over anticancer activity, potentially missing therapeutically relevant compounds. To a...
Lelisse T. Umeta, J. Mallareddy, Sarbjit Singh et al.· Molecular Biomedicine· 0 citations
Lysosome-targeting chimeras (LYTACs) have attracted much attention due to their ability to specifically target and degrade disease-related proteins on the cell membrane. However, their clinical application is limited by poor tumor specificity, systemic off-target effects, and a lack of temporal regulation. Engineered b...
Shan Sun, Ruo-Xi Hu, Xue Zhai et al.· Journal of Controlled Releas...· 0 citations
Targeted protein degradation (TPD) represents an emerging paradigm in drug discovery, capable of overcoming the limitations of traditional therapeutic strategies based on protein inhibition. Exploiting the ubiquitin–proteasome system (UPS), TPD allows the selective elimination of pathologically relevant proteins. The m...
M. Aliberti, M. Chini, Giuseppe Bifulco et al.· ChemBioChem· 0 citations
A yeast-based, gain-of-growth, high-throughput screening assay for the identification of small-molecule modulators of mitochondrial protein import and identifying compounds for downstream validation in mammalian systems is described.
Maya Cielo Cornejo, Sandy Che-Eun S. Lee, Christina Q. Nguyen et al.· Assay and drug development t...· 0 citations